Previous studies have shown that EGFR mutations are associated with a low response rate to PD-1/PD-L1 inhibitors in NSCLC, and objective responses were observed in 1 of 28 (3.6%) EGFR-mutant patients versus 7 of 30 (23.3%) EGFR wild-type patients [15]. Here, CD274 is linked to non-small cell lung carcinoma.